LEXEO Therapeutics Launches with $85 Million Series A Financing to Develop Gene Therapies for Rare and Non-Rare Monogenic Diseases
January 07, 2021 07:30 ET
|
LEXEO Therapeutics
Rare disease and gene therapy industry veterans Steven Altschuler, M.D., R. Nolan Townsend and Jay Barth, M.D., team up with gene therapy pioneer Ronald Crystal, M.D., to launch fully integrated gene...
CENTOGENE Expands Partnership with PTC Therapeutics to Generate New Insights for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency
November 25, 2020 06:30 ET
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and HEIDELBERG, Germany and BERLIN, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that...
CENTOGENE Announces Leadership Transition
October 20, 2020 06:00 ET
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...
CENTOGENE Increases Full-Year 2020 Guidance
October 20, 2020 05:30 ET
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...
CENTOGENE Receives FDA Emergency Use Authorization for SARS-CoV-2 RT-PCR Assay for Individuals Without Symptoms or Other Reasons to Suspect COVID-19
October 19, 2020 06:30 ET
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...
CENTOGENE’s Information Security Management System Awarded ISO/IEC 27001:2017 Accreditation
September 28, 2020 06:30 ET
|
CENTOGENE GmbH
Company awarded ISO 27001 Accreditation for its Information Security Management SystemThe internationally recognized certification is set by the International Organization for Standardization (ISO),...
CentoMD® Update Reveals Further Insights Into Rare Diseases
August 11, 2020 06:30 ET
|
CENTOGENE GmbH
CAMBRIDGE, Mass., and ROSTOCK and BERLIN, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and...